Cargando…

Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy

Melanoma is responsible for most skin cancer-related deaths and is one of the most common cancers diagnosed in young adults. In melanoma, tumors can become established by activation of the negative regulator of cytotoxic T lymphocytes (CTLs), CTL antigen-4 (CTLA-4). Ipilimumab blocks the interaction...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mozzillo, Nicola, Simeone, Ester, Benedetto, Lucia, Curvietto, Marcello, Giannarelli, Diana, Gentilcore, Giusy, Camerlingo, Rosa, Capone, Mariaelena, Madonna, Gabriele, Festino, Lucia, Caracò, Corrado, Di Monta, Gianluca, Marone, Ugo, Di Marzo, Massimiliano, Grimaldi, Antonio M, Mori, Stefano, Ciliberto, Gennaro, Ascierto, Paolo A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485758/ https://www.ncbi.nlm.nih.gov/pubmed/26155423 http://dx.doi.org/10.1080/2162402X.2015.1008842

Ejemplares similares

Combination therapy with ipilimumab and electrochemotherapy: preliminary efficacy results and correlation with immunological parameters
por: Simeone, Ester, et al.
Publicado: (2014)

Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis
por: Di Monta, Gianluca, et al.
Publicado: (2017)

Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis
por: Caracò, Corrado, et al.
Publicado: (2013)

MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
por: Bifulco, Carlo, et al.
Publicado: (2014)

Long-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma
por: Mozzillo, Nicola, et al.
Publicado: (2014)

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients
por: Grimaldi, Antonio Maria, et al.
Publicado: (2015)

Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
por: Grimaldi, Antonio M, et al.
Publicado: (2014)

The abscopal effect: efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
por: Grimaldi, Antonio M, et al.
Publicado: (2013)

High expression of a spliced variant of FKBP51 in peripheral blood mononuclear cells of melanoma patients may be related to PDL-1 on tumour and predictive of response to Ipilimumab
por: Simeone, Ester, et al.
Publicado: (2014)

Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma
por: Mozzillo, Nicola, et al.
Publicado: (2012)

Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients
por: Simeone, Ester, et al.
Publicado: (2015)

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
por: Capone, Mariaelena, et al.
Publicado: (2018)

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
por: Grimaldi, Antonio M, et al.
Publicado: (2014)

Serious haematological toxicity during and after ipilimumab treatment: a case series
por: Simeone, Ester, et al.
Publicado: (2014)

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
por: Stucci, Stefania, et al.
Publicado: (2015)

Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients
por: Tallerico, Rossana, et al.
Publicado: (2015)

Ipilimumab and Stereotactic Radiosurgery with CyberKnife(®) System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience
por: Borzillo, Valentina, et al.
Publicado: (2021)

Clinicopathologic features and surgical management of primary umbilical melanoma: a case series
por: Di Monta, Gianluca, et al.
Publicado: (2015)

Immunoscore: a new possible approach for melanoma classification
por: Capone, Mariaelena, et al.
Publicado: (2014)

Collagen sealant patch to reduce lymphatic drainage after lymph node dissection
por: Di Monta, Gianluca, et al.
Publicado: (2012)

Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors
por: Mozzillo, Nicola, et al.
Publicado: (2013)

Main roads to melanoma
por: Palmieri, Giuseppe, et al.
Publicado: (2009)

Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations
por: Gentilcore, Giusy, et al.
Publicado: (2013)

Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for clinical response biomarker identification
por: Hotson, Drew, et al.
Publicado: (2013)

Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment
por: Ascierto, Paolo A, et al.
Publicado: (2010)

Do BRAF inhibitors select for populations with different disease progression kinetics?
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification
por: Hotson, Drew, et al.
Publicado: (2014)

Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma
por: Harder, Nathalie, et al.
Publicado: (2019)

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
por: Morello, Silvana, et al.
Publicado: (2017)

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
por: Simeone, Ester, et al.
Publicado: (2021)

PD-L1(+) neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab
por: Cristinziano, Leonardo, et al.
Publicado: (2022)

IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab
por: Mallardo, Domenico, et al.
Publicado: (2023)

Potential clinical implications of CD4(+)CD26(high) T cells for nivolumab treated melanoma patients
por: Galati, Domenico, et al.
Publicado: (2023)

Effect of electrochemotherapy on human herpesvirus 8 kinetics in classic Kaposi sarcoma
por: Starita, Noemy, et al.
Publicado: (2017)

Metastatic eccrine porocarcinoma: report of a case and review of the literature
por: Marone, Ugo, et al.
Publicado: (2011)

Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
por: Madonna, Gabriele, et al.
Publicado: (2021)

NF-κB as potential target in the treatment of melanoma
por: Madonna, Gabriele, et al.
Publicado: (2012)

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
por: Marchetti, Paolo, et al.
Publicado: (2020)

Lymphoscintigraphy Defines New Lymphatic Pathways from Cutaneous Melanoma Site: Clinical Implications and Surgical Management
por: Marone, Ugo, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_lilkb76kpg1t522r3gkps8i866